ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis

Cancer shared this article with you from Inoreader ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis Via Cancer Gene Therapy - Issue - nature.com science feeds Cancer Gene Therapy, Published online: 17 October 2020; doi:10.1038/s41417-020-00245-w ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.